News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


KEYTRUDA® registered for treatment of lung cancer

News Release


KEYTRUDA® registered for treatment of lung cancer


April 20, 2017, Merck Sharp & Dohme Limited (MSD) today announced KEYTRUDA® (pembrolizumab) has now received its second Medsafe registration for lung cancer.

KEYTRUDA, which was funded for melanoma last year, is now registered for PD-L1 positive patients in both pre-treated and untreated advanced non-small cell lung cancer (NSCLC).

Paul Smith, MSD New Zealand Director, says, “This KEYTRUDA registration has the potential to transform the way lung cancer is treated in New Zealand and is particularly important for patients who express PD-L1. PD-L1 is a protein expressed by cancer cells to evade the immune system.

“The recent KEYNOTE-024 clinical trial results have been so compelling that trial investigators believe KEYTRUDA should replace platinum-based chemotherapy to become the new “Standard of Care” for untreated advanced NSCLC that expresses high levels of PD-L1. 1

“Chemotherapy has long been the standard of care for advanced NSCLC; however the latest data from the KEYNOTE-024 trial demonstrates superior overall survival with KEYTRUDA, compared to chemotherapy in patients with high PD-L1 expression.2

“In light of that trial data, the external data and safety monitoring committee recommended that the study be stopped early to give the patients who were receiving chemotherapy the opportunity to receive KEYTRUDA.” 2

“Lung cancer is New Zealand’s biggest cancer killer, accounting for more than 1,600 deaths per year. 3 More people die of lung cancer, than of breast cancer, prostate cancer and melanoma combined.” 3

Philip Hope, CEO of Lung Foundation New Zealand, says, “This KEYTRUDA lung cancer registration is a hugely welcome step forward in ensuring New Zealanders can benefit from this new generation of treatments. I hope that this medicine will be made available on a funded basis to all New Zealanders with life-threatening lung cancer.

“As New Zealanders we need to acknowledge the gravity of this disease and look at ways we can work together to prevent it, treat it and ultimately save lives. Lung cancer often affects the most disadvantaged with male lung cancer rates in the most deprived areas 3.2 times higher than those in the least deprived areas. 4

“Lung cancer can affect anyone, not just smokers; in fact, one in five people diagnosed with lung cancer have never smoked. 3

“It also has a significant impact on Maori compared to the non-Maori population with rates three - four times higher in Maori men and women respectively.” 5

Paul Smith says, “MSD has made an application to PHARMAC for funding of KEYTRUDA in advanced NSCLC. We hope that PHARMAC can work with urgency to provide lung cancer patients with a new treatment option, and we believe it is possible to fund KEYTRUDA for this group of patients as early as 1 July.

“Patients wanting to access KEYTRUDA should seek further advice from their cancer specialist about the options that may benefit them.”

-ENDS-


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Howard Davis: Never Too Old To Rock & Roll - Jethro Tull

As Greil Marcus recently observed in an NYRB review of Robbie Robertson's autobiographical Testimony, in rock and roll there is always an origin story. In the case of Jethro Tull founder Ian Anderson, he claims to have been influenced by his father's big band and jazz record collections and the emergence of rock music in the 1950s, but became disenchanted with the "show biz" style of early US stars like Elvis Presley... More>>

October: Alice Cooper Returns To NZ

It was March 1977 when Alice Cooper undertook his first ever concert tour of New Zealand – and broke attendance records. 40 years on and this revered entertainer continues to surprise and exude danger at every turn, thrilling audiences globally! More>>

ALSO:

Howard Davis Review: The Contemporary Relevance Of Denial

Denial has all the hallmarks of a riveting courtroom drama. Based on a 1996 British libel case that author David Irving brought against Lipstadt, the movie has been criticized as flat and stagey, but it nonetheless conveys a visceral clarity of vision and sense of overwhelming urgency. More>>

Obituary: John Clarke Dies Aged 68

Andrew Little: “I grew up with Fred Dagg and I am devastated by John Clarke’s death. He taught us to laugh at ourselves and more importantly laugh at our politicians.” More>>

ALSO:

Howard Davis: Colin McCahon's 'on Going Out With The Tide'

Curated by Wystan Curnow and Robert Leonard, On Going Out with the Tide features major works that have been assembled from public and private collections across New Zealand and Australia. It focusses on McCahon’s evolving engagement with Māori subjects and themes, ranging from early treatments of koru imagery to later history paintings which refer to Māori prophets and investigate land-rights issues. More>>

Howard Davis: Rodger Fox Gets Out The Funk

By now a living New Zealand legend, band leader and trombonist Rodger Fox has performed with some of the biggest names in the jazz business, including Louie Bellson, Bill Reichenbach, Chuck Findley, Randy Crawford, Bobby Shew, Lanny Morgan, Bruce Paulson, Diane Schuur, Arturo Sandoval, David Clayton-Thomas, and Joe Williams, to name only a few. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news